Saturn V Capital Management’s Trevi Therapeutics TRVI Stock Holding History

Saturn V Capital Management’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19.6M	Buy	+1,052,043	New	+$15.3M	2.81%	14

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Saturn V Capital Management's TRVI Position: Q2 2026 in Review

Saturn V Capital Management opened a new position in Trevi Therapeutics (TRVI) in Q2 2026: 1,052,043 shares worth $19.6M. The stake represents 2.81% of the portfolio and ranks #14 among its holdings.

217 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

Saturn V Capital Management held 1,052,043 shares of Trevi Therapeutics worth $19.6M as of Q2 2026.
Trevi Therapeutics was a new Saturn V Capital Management position in Q2 2026.
Trevi Therapeutics made up 2.81% of Saturn V Capital Management's portfolio in Q2 2026, its #14 holding.
217 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Saturn V Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.